STAT+:GLP-1类药物因罕见眼部疾病风险被给予FDA警告
摘要
想紧跟当今推动生物技术发展的科学与政治动态吗?注册即可在我们的生物技术新闻简报中接收内容。早上好。我们有很多新闻,将直接进入正题。今早须知:Beam Therapeutics表示,其基于CRISPR的镰状细胞病治疗达到了关键临床试验的主要目标——至少12个月内免于严重疼痛危机。未披露详细数据,但Beam表示将最早于今年年底为名为risto-cel的该疗法提交FDA上市申请。PepGen在肌营养不良症方面显示有希望的数据。生物技术公司PepGen今早表示,其试验性药物在一项关键指标上显示出,在治疗一种常见类型肌营养不良的竞争中迄今最有希望的早期数据
English
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’ve got lots of news that we’ll get straight into. The need-to-know this morning Beam Therapeutics said its CRISPR-based treatment for sickle cell disease achieved the primary goal of a pivotal clinical trial — freedom from severe pain crises for at least 12 months. No detailed data were disclosed, but Beam said it would file an FDA marketing application for the therapy, called risto-cel, as soon as the end of this year. PepGen shows promising data for muscular dystrophy The biotech company PepGen said this morning that its experimental drug had shown, by one key measure, the most promising early data yet in the race to treat a commmon type of muscular